Literature DB >> 17012456

Annual costs associated with diagnosis of uterine leiomyomata.

Katherine E Hartmann1, Howard Birnbaum, Rym Ben-Hamadi, Eric Q Wu, Max H Farrell, James Spalding, Paul Stang.   

Abstract

OBJECTIVE: To describe the annual care, direct health care, and indirect work loss costs for women with a diagnosis of uterine leiomyomata.
METHODS: We examined data from an employer claims database of 1.2 million beneficiaries (1999 to 2003). Analysis was restricted to women with at least 12 months of continuous coverage and ages 18 to 64 years with at least one diagnosis of leiomyomata (International Classification of Diseases, 9th Revision, 218.xx, 654.1x). We selected a comparison group of women without a leiomyoma diagnosis using a 1:1 match on age, employment, region, health plan type, and length of enrollment. We compared resource use, disability claims, and excess costs in the year after the index diagnosis.
RESULTS: The average age of women diagnosed with leiomyomata in this study was 43.7 years. Women with leiomyomata (N = 5,122) had more clinic visits (relative risk [RR] 1.2, 95% confidence interval [CI] 1.2-1.2), diagnostic tests (RR 3.1, 95% CI 2.9-3.2), and procedures (RR 34.6, 95% CI 25.8-46.5) than controls (N = 5,122). Within 1 year of the diagnosis of leiomyomata, 42% of women had a complete blood count, 66% had pelvic imaging, and 30% had surgery (68% of surgical procedures involved hysterectomy). Women with leiomyomata were 3-fold more likely to have disability claims (RR 3.1, 95% CI 2.7-3.6). Estimated average annual excess cost for each woman with leiomyomata (adjusted for confounders) was Dollars 4,624 (Dollars 771 in work loss costs). Total costs for women with leiomyomata were 2.6 times greater than for controls.
CONCLUSION: Diagnosed uterine leiomyomata are associated with increased resource use and with substantially higher health care and work loss costs. LEVEL OF EVIDENCE: II-3.

Entities:  

Mesh:

Year:  2006        PMID: 17012456     DOI: 10.1097/01.AOG.0000234651.41000.58

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  49 in total

1.  Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma.

Authors:  Zehra Ordulu; Paola Dal Cin; Wilson W S Chong; Kwong Wai Choy; Charles Lee; Michael G Muto; Bradley J Quade; Cynthia C Morton
Journal:  Genes Chromosomes Cancer       Date:  2010-12       Impact factor: 5.006

2.  Genome-wide analysis of loss of heterozygosity and copy number amplification in uterine leiomyomas using the 100K single nucleotide polymorphism array.

Authors:  Kellen L Meadows; Danica M K Andrews; Zongli Xu; Gleta K Carswell; Shannon K Laughlin; Donna D Baird; Jack A Taylor
Journal:  Exp Mol Pathol       Date:  2011-04-08       Impact factor: 3.362

3.  The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters.

Authors:  Karen L Huyck; Carolien I M Panhuysen; Karen T Cuenco; Jingmei Zhang; Hilary Goldhammer; Emlyn S Jones; Priya Somasundaram; Allison M Lynch; Bernard L Harlow; Hang Lee; Elizabeth A Stewart; Cynthia C Morton
Journal:  Am J Obstet Gynecol       Date:  2008-02       Impact factor: 8.661

4.  BET1L and TNRC6B associate with uterine fibroid risk among European Americans.

Authors:  Todd L Edwards; Kara A Michels; Katherine E Hartmann; Digna R Velez Edwards
Journal:  Hum Genet       Date:  2013-04-19       Impact factor: 4.132

5.  Enhancing uterine fibroid research through utilization of biorepositories linked to electronic medical record data.

Authors:  Lani Feingold-Link; Todd L Edwards; Sarah Jones; Katherine E Hartmann; Digna R Velez Edwards
Journal:  J Womens Health (Larchmt)       Date:  2014-12       Impact factor: 2.681

6.  Identifying the molecular signature of the interstitial deletion 7q subgroup of uterine leiomyomata using a paired analysis.

Authors:  Jennelle C Hodge; Peter J Park; Jonathan M Dreyfuss; Iman Assil-Kishawi; Priya Somasundaram; Luwam G Semere; Bradley J Quade; Allison M Lynch; Elizabeth A Stewart; Cynthia C Morton
Journal:  Genes Chromosomes Cancer       Date:  2009-10       Impact factor: 5.006

7.  Cytokine patterns differ seasonally between women with and without uterine leiomyomata.

Authors:  Ganesa Wegienka; Donna Day Baird; Tracy Cooper; Kimberley J Woodcroft; Suzanne Havstad
Journal:  Am J Reprod Immunol       Date:  2013-04-25       Impact factor: 3.886

8.  MED12 exon 2 mutations in histopathological uterine leiomyoma variants.

Authors:  Netta Mäkinen; Pia Vahteristo; Kati Kämpjärvi; Johanna Arola; Ralf Bützow; Lauri A Aaltonen
Journal:  Eur J Hum Genet       Date:  2013-02-27       Impact factor: 4.246

9.  Growth of uterine leiomyomata among premenopausal black and white women.

Authors:  Shyamal D Peddada; Shannon K Laughlin; Kelly Miner; Jean-Philippe Guyon; Karen Haneke; Heather L Vahdat; Richard C Semelka; Ania Kowalik; Diane Armao; Barbara Davis; Donna Day Baird
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-01       Impact factor: 11.205

10.  Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids.

Authors:  Amy K O'Sullivan; David Thompson; Paula Chu; David W Lee; Elizabeth A Stewart; Milton C Weinstein
Journal:  Int J Technol Assess Health Care       Date:  2009-01       Impact factor: 2.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.